Sumary of A ‘promising’ treatment for Alzheimer’s has arrived and it could ‘transform’ lives – study:
- New research published today draws attention to a novel approach to potentially treating Alzheimer’s disease – the most common type of dementia characterised by memory loss.
- Rather than focus on the amyloid beta protein in plaques in the brain, which are commonly associated with Alzheimer’s disease, the antibody and vaccine both target a different soluble form of the protein, which is thought to be highly toxic.
- Amyloid beta protein naturally exists as highly flexible, string-like molecules in solution, which can join together to form fibres and plaques.
- Professor Thomas Bayer, from the University Medical Center Göttingen, said: “In clinical trials, none of the potential treatments which dissolve amyloid plaques in the brain have shown much success in terms of reducing Alzheimer’s symptoms.
- We identified an antibody in mice that would neutralise the truncated forms of soluble amyloid beta, but would not bind either to normal forms of the protein or to the plaques.
- ”DON’T MISSThe everyday food item potentially causing cancer [INSIGHT]The breakfast drink that’s a ‘hard no’ in the morning [TIPS]Dementia diet: Common food type to eat everyday [TIPS]Doctor Preeti Bakrania and colleagues from LifeArc adapted this antibody so a human immune system wouldn’t recognise it as foreign and would accept it.
- When the Leicester research group looked at how and where this “humanised” antibody, called TAP01_04, was binding to the truncated form of amyloid beta, the team had a surprise.
- They saw the amyloid beta protein was folded back on itself, in a hairpin-shaped structure.